• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于浇铸脂质共混物的控释植入物。

Controlled release implants based on cast lipid blends.

机构信息

Univ. Lille Nord de France, College of Pharmacy, 3, rue du Professeur Laguesse, 59006 Lille, France.

出版信息

Eur J Pharm Sci. 2011 May 18;43(1-2):78-83. doi: 10.1016/j.ejps.2011.03.013. Epub 2011 Apr 2.

DOI:10.1016/j.ejps.2011.03.013
PMID:21463679
Abstract

The aim of this study was to use lipid:lipid blends as matrix formers in controlled release implants. The systems were prepared by melting and casting and thoroughly characterized before and after exposure to the release medium. Based on the experimental results, a mechanistic realistic mathematical model was used to get further insight into the underlying drug release mechanisms. Importantly, broad spectra of drug release patterns could be obtained by simply varying the lipid:lipid blend ratio in implants based on Precirol ATO 5 (glyceryl palmitostearate):Dynasan 120 (hardened soybean oil) mixtures loaded with propranolol hydrochloride. Release periods ranging from a few days up to several months could be provided. Interestingly, the drug release rate monotonically decreased with increasing Dynasan 120 content, except for implants containing about 20-25% Precirol, which exhibited surprisingly high release rates. This could be attributed to the incomplete miscibility of the two lipids at these blend ratios: DSC thermograms showed phase separation in these systems. This is likely to cause differences in the implants' microstructure, which determines the mobility of water and dissolved drug as well as the mechanical stability of the systems. Purely diffusion controlled drug release was only observed at Precirol ATO 5 contents around 5-10%. In all other cases, limited drug solubility effects or matrix former erosion are also expected to play a major role. Thus, lipid:lipid blends are very interesting matrix formers in controlled release implants. However, care must be taken with respect to the mutual miscibility of the compounds: in case of phase separation, surprisingly high drug release rates might be observed.

摘要

本研究旨在将脂质

脂质混合物用作控释植入物中的基质形成剂。通过熔融和浇铸制备了这些系统,并在暴露于释放介质前后进行了彻底的表征。基于实验结果,使用机械现实的数学模型进一步深入了解潜在的药物释放机制。重要的是,通过简单地改变基于 Precirol ATO 5(甘油棕榈硬脂酸酯):Dynasan 120(硬化大豆油)混合物的植入物中的脂质:脂质混合物比例,可以获得广泛的药物释放模式谱,其中载有盐酸普萘洛尔。可以提供从几天到几个月的释放期。有趣的是,除了含有约 20-25% Precirol 的植入物外,药物释放速率随着 Dynasan 120 含量的增加而单调降低,这些植入物表现出出人意料的高释放速率。这可以归因于两种脂质在这些混合物比例下不完全混溶性:DSC 热图谱显示这些系统中存在相分离。这很可能导致植入物微观结构的差异,从而决定了水和溶解药物的迁移率以及系统的机械稳定性。仅在 Precirol ATO 5 含量约为 5-10%时才观察到纯扩散控制的药物释放。在所有其他情况下,预计药物溶解度有限或基质形成剂侵蚀也将发挥主要作用。因此,脂质:脂质混合物是控释植入物中非常有趣的基质形成剂。然而,必须注意化合物之间的互溶性:在出现相分离的情况下,可能会观察到出人意料的高药物释放速率。

相似文献

1
Controlled release implants based on cast lipid blends.基于浇铸脂质共混物的控释植入物。
Eur J Pharm Sci. 2011 May 18;43(1-2):78-83. doi: 10.1016/j.ejps.2011.03.013. Epub 2011 Apr 2.
2
Drug release mechanisms of compressed lipid implants.压缩脂质植入物的药物释放机制。
Int J Pharm. 2011 Feb 14;404(1-2):27-35. doi: 10.1016/j.ijpharm.2010.10.048. Epub 2010 Nov 3.
3
MALDI-TOF MS imaging of controlled release implants.基质辅助激光解吸电离飞行时间质谱成像技术在控释植入物中的应用。
J Control Release. 2012 Jul 10;161(1):98-108. doi: 10.1016/j.jconrel.2012.04.017. Epub 2012 Apr 19.
4
Cast lipid implants for controlled drug delivery: importance of the tempering conditions.铸造脂质植入物用于控制药物释放:回火条件的重要性。
J Pharm Sci. 2011 Aug;100(8):3471-3481. doi: 10.1002/jps.22574. Epub 2011 May 4.
5
Influence of poloxamers on the dissolution performance and stability of controlled-release formulations containing Precirol ATO 5.泊洛沙姆对含有Precirol ATO 5的控释制剂的溶出性能和稳定性的影响。
Int J Pharm. 2006 Feb 17;309(1-2):6-15. doi: 10.1016/j.ijpharm.2005.10.042. Epub 2005 Dec 20.
6
Drug release from extruded solid lipid matrices: theoretical predictions and independent experiments.挤出固体脂质基质中的药物释放:理论预测与独立实验。
Eur J Pharm Biopharm. 2012 Jan;80(1):122-9. doi: 10.1016/j.ejpb.2011.10.002. Epub 2011 Oct 8.
7
Drug release mechanisms of cast lipid implants.脂质植入剂的药物释放机制。
Eur J Pharm Biopharm. 2011 Aug;78(3):394-400. doi: 10.1016/j.ejpb.2011.02.011. Epub 2011 Feb 23.
8
A novel mathematical model quantifying drug release from lipid implants.一种量化脂质植入物药物释放的新型数学模型。
J Control Release. 2008 Jun 24;128(3):233-40. doi: 10.1016/j.jconrel.2008.03.009. Epub 2008 Mar 18.
9
Solid lipid extrusion of sustained release dosage forms.缓释剂型的固体脂质挤出技术。
Eur J Pharm Biopharm. 2007 Sep;67(2):440-8. doi: 10.1016/j.ejpb.2007.03.008. Epub 2007 Mar 16.
10
Drug release from lipid-based implants: elucidation of the underlying mass transport mechanisms.基于脂质的植入物的药物释放:潜在传质机制的阐释。
Int J Pharm. 2006 May 18;314(2):137-44. doi: 10.1016/j.ijpharm.2005.08.030. Epub 2006 Feb 28.

引用本文的文献

1
Additive manufacturing of water-soluble 3D micro molds for complex-shaped lipid microparticles.用于复杂形状脂质微粒的水溶性3D微模具的增材制造。
Nat Commun. 2025 Feb 18;16(1):1734. doi: 10.1038/s41467-025-56984-7.
2
Biobased Ionic Liquids as Multitalented Materials in Lipidic Drug Implants.生物基离子液体作为脂质药物植入物中的多功能材料。
Pharmaceutics. 2021 Jul 28;13(8):1163. doi: 10.3390/pharmaceutics13081163.
3
Investigation on Secondary Structure Alterations of Protein Drugs as an Indicator of Their Biological Activity Upon Thermal Exposure.
探讨蛋白质药物的二级结构变化作为其热暴露后生物活性的指标。
Protein J. 2019 Oct;38(5):551-564. doi: 10.1007/s10930-019-09837-4.
4
Solvent-free melting techniques for the preparation of lipid-based solid oral formulations.用于制备脂质基固体口服制剂的无溶剂熔融技术。
Pharm Res. 2015 May;32(5):1519-45. doi: 10.1007/s11095-015-1661-y. Epub 2015 Mar 19.